Wealth Enhancement Advisory Services LLC Sells 15,982 Shares of Sanofi (NASDAQ:SNY)

Wealth Enhancement Advisory Services LLC cut its stake in shares of Sanofi (NASDAQ:SNY) by 21.5% in the 1st quarter, HoldingsChannel reports. The firm owned 58,380 shares of the company’s stock after selling 15,982 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Sanofi were worth $3,238,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of SNY. Brighton Jones LLC lifted its position in Sanofi by 52.6% during the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock valued at $261,000 after purchasing an additional 1,869 shares during the last quarter. IFP Advisors Inc lifted its position in Sanofi by 17.2% during the fourth quarter. IFP Advisors Inc now owns 2,132 shares of the company’s stock valued at $103,000 after purchasing an additional 313 shares during the last quarter. Lake Street Advisors Group LLC lifted its position in Sanofi by 6.0% during the fourth quarter. Lake Street Advisors Group LLC now owns 7,121 shares of the company’s stock valued at $343,000 after purchasing an additional 406 shares during the last quarter. Whipplewood Advisors LLC bought a new stake in Sanofi during the fourth quarter valued at approximately $76,000. Finally, NewEdge Wealth LLC lifted its position in Sanofi by 20.5% during the fourth quarter. NewEdge Wealth LLC now owns 32,799 shares of the company’s stock valued at $1,582,000 after purchasing an additional 5,591 shares during the last quarter. 14.04% of the stock is currently owned by institutional investors.

Sanofi Stock Down 1.1%

Shares of NASDAQ SNY opened at $47.85 on Friday. The company has a quick ratio of 0.69, a current ratio of 1.37 and a debt-to-equity ratio of 0.16. Sanofi has a 52 week low of $45.80 and a 52 week high of $60.12. The firm’s fifty day moving average is $50.95 and its 200 day moving average is $51.99. The company has a market cap of $117.35 billion, a price-to-earnings ratio of 17.09, a PEG ratio of 1.00 and a beta of 0.50.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, April 24th. The company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.90 by $0.04. Sanofi had a net margin of 14.56% and a return on equity of 17.15%. The company had revenue of $10.41 billion for the quarter, compared to the consensus estimate of $9.79 billion. During the same period in the previous year, the firm earned $1.78 earnings per share. The firm’s revenue for the quarter was down 11.0% on a year-over-year basis. On average, equities research analysts expect that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Increases Dividend

The company also recently announced an annual dividend, which was paid on Thursday, June 12th. Investors of record on Friday, May 9th were paid a $2.0369 dividend. This represents a dividend yield of 3.1%. This is an increase from Sanofi’s previous annual dividend of $1.48. The ex-dividend date of this dividend was Friday, May 9th. Sanofi’s payout ratio is presently 57.14%.

Analyst Upgrades and Downgrades

SNY has been the subject of a number of recent research reports. BNP Paribas initiated coverage on shares of Sanofi in a report on Tuesday, April 15th. They issued an “outperform” rating and a $65.00 price objective for the company. Guggenheim restated a “buy” rating on shares of Sanofi in a report on Tuesday, June 3rd. The Goldman Sachs Group initiated coverage on shares of Sanofi in a report on Friday, March 21st. They issued a “neutral” rating and a $65.00 price objective for the company. Hsbc Global Res upgraded shares of Sanofi to a “strong-buy” rating in a report on Monday, April 28th. Finally, Morgan Stanley set a $56.00 price objective on shares of Sanofi in a report on Monday, June 2nd. Three equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $61.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.